Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDICT Study of pivmecillinam prophylaxis after kidney transplantation
2026-527337-63-00Phase 3Authorised
- Sponsor
- Capital Region of Denmark
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Symptomatic Bacteriuria and bloodstream infection (BSI) comparing Pivmecillinam prophylaxis with Placebo (2 arms). Primary endpoint: Composite Enterobacterales urinary tract infection and/or bloodstream infection incidence. Planned start Oct 2026; status: authorised.
02
Drugs
pivmecillinam
03
Conditions
Symptomatic Bacteriuriabloodstream infection (BSI)
Beyond the preview
Go deeper on 2026-527337-63-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527337-63-00.